Alector, Inc. (ALEC)

NMS – Цена в реальном времени. Валюта: USD

1.86

+0.01 (0.54%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

1.86

0.00 (0.00%)

После закрытия: Jun 26, 2026, 6:37 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Alector, Inc. (ALEC)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Alector, Inc. (ALEC)

Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates

Alector Reports First Quarter 2026 Financial Results and Provides Business Update

Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis

Alector (ALEC)'s Technical Outlook is Bright After Key Golden Cross

Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles

Alector, Inc. (ALEC) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Видео

No Data

Пресс-релизы

Alector Reports First Quarter 2026 Financial Results and Provides Business Update

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis

Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Alector to Participate in the TD Cowen 46th Annual Health Care Conference

Search stocks

Alector, Inc. (ALEC)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Alector, Inc. (ALEC)

Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates

Alector Reports First Quarter 2026 Financial Results and Provides Business Update

Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis

Alector (ALEC)'s Technical Outlook is Bright After Key Golden Cross

Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles

Alector, Inc. (ALEC) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Видео

No Data

Пресс-релизы

Alector Reports First Quarter 2026 Financial Results and Provides Business Update

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis

Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Alector to Participate in the TD Cowen 46th Annual Health Care Conference